{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:23:09Z","timestamp":1785435789251,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Premenopausal women diagnosed with estrogen receptor (ER)-positive breast cancer are prescribed 5\u201310 years of tamoxifen therapy to prevent or delay a recurrence. The enzymes 17\u03b2-hydroxysteroid dehydrogenase 1 and 2 (HSD17B1 and HSD17B2, respectively) regulate the relative concentrations of estrogen metabolites and may modify tamoxifen effectiveness. We evaluated the prognostic and predictive value of HSD17B1 and HSD17B2 expression in breast tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified a cohort of premenopausal breast cancer patients from the Danish Breast Cancer Group database (2002\u20132011) and stratified on ER status and receipt of tamoxifen (4600 ER+\/TAM\u2009+\u2009and 1359 ER\u2212\/TAM\u2212). Biomarkers HSD17B1 and HSD17B2 were assayed by immunohistochemistry. We used Cox proportional hazards regression to compute the hazard ratios (HRs) and 95% simulation intervals (SIs) associating each biomarker with recurrence, with bias adjustment to account for mismeasurement of biomarker expression and baseline selection bias from tumor sample availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among ER+\/TAM\u2009+\u2009breast cancers, 24% had any HSD17B1 expression compared with 13% of ER\u2212\/TAM\u2009\u2212\u2009breast cancers. In the bias-adjusted analyses, women diagnosed with tumors positive for HSD17B1 expression had a slight increased rate of recurrence: HR\u2009=\u20091.13 (95% SI 0.90, 1.43) in the ER+\/TAM\u2009+\u2009stratum and HR\u2009=\u20091.15 (95% SI 0.77, 1.79) in the ER\u2212\/TAM \u2212 stratum. A 10-unit increase in HSD17B2 expression corresponded with a decrease in the estimated rate of recurrence among ER+\/TAM\u2009+\u2009patients (HR\u2009=\u20090.85, 95% SI 0.69, 1.05), but not among ER\u2212\/TAM \u2212 patients (HR\u2009=\u20091.07, 95% SI 0.82, 1.42).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HSD17B1 may be a prognostic marker for recurrence and HSD17B2 may be predictive of response to tamoxifen therapy in breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-025-02196-2","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T06:54:56Z","timestamp":1767077696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["17\u03b2-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark"],"prefix":"10.1186","volume":"28","author":[{"given":"Lindsay J.","family":"Collin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Woolpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Kjaersgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Ahern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Damkier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina L.","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer M.","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre P.","family":"Cronin-Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Lash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"1","key":"2196_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3322\/caac.21320","volume":"66","author":"CE DeSantis","year":"2016","unstructured":"DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31\u201342. https:\/\/doi.org\/10.3322\/caac.21320.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"2196_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1701830.","journal-title":"N Engl J Med"},{"issue":"3","key":"2196_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/jnci\/djab202","volume":"114","author":"RN Pedersen","year":"2022","unstructured":"Pedersen RN, Esen B\u00d6, Mellemkj\u00e6r L, et al. The incidence of breast cancer recurrence 10\u201332 years after primary diagnosis. J Natl Cancer Inst. 2022;114(3):391\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab202.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2196_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/oxfordjournals.epirev.a036115","volume":"15","author":"JL Kelsey","year":"1993","unstructured":"Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36\u201347. https:\/\/doi.org\/10.1093\/oxfordjournals.epirev.a036115.","journal-title":"Epidemiol Rev"},{"issue":"8","key":"2196_CR5","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(8):1533\u201346. https:\/\/doi.org\/10.1093\/annonc\/mdv221.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2196_CR6","doi-asserted-by":"publisher","unstructured":"Buckley MMT, Goa KL, Tamoxifen. Drugs. 1989;37(4):451\u201390. https:\/\/doi.org\/10.2165\/00003495-198937040-00004.","DOI":"10.2165\/00003495-198937040-00004"},{"issue":"1","key":"2196_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","volume":"32","author":"WL Miller","year":"2011","unstructured":"Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81\u2013151. https:\/\/doi.org\/10.1210\/er.2010-0013.","journal-title":"Endocr Rev"},{"issue":"1\u20132","key":"2196_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mce.2003.12.006","volume":"218","author":"R Mindnich","year":"2004","unstructured":"Mindnich R, M\u00f6ller G, Adamski J. The role of 17 beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol. 2004;218(1\u20132):7\u201320. https:\/\/doi.org\/10.1016\/j.mce.2003.12.006.","journal-title":"Mol Cell Endocrinol"},{"issue":"18","key":"2196_CR9","doi-asserted-by":"publisher","first-page":"30552","DOI":"10.18632\/oncotarget.15547","volume":"8","author":"E Hilborn","year":"2017","unstructured":"Hilborn E, St\u00e5l O, Jansson A. Estrogen and androgen-converting enzymes 17\u03b2-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17\u03b2-hydroxysteroid dehydrogenase type 1, 2, and breast cancer. Oncotarget. 2017;8(18):30552\u201362. https:\/\/doi.org\/10.18632\/oncotarget.15547.","journal-title":"Oncotarget"},{"issue":"4","key":"2196_CR10","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1210\/me.2009-0468","volume":"24","author":"JA Aka","year":"2010","unstructured":"Aka JA, Mazumdar M, Chen CQ, Poirier D, Lin SX. 17\u03b2-Hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol Endocrinol. 2010;24(4):832\u201345. https:\/\/doi.org\/10.1210\/me.2009-0468.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"2196_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1054\/bjoc.1999.0956","volume":"82","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, Sasano H. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer. 2000;82(3):518\u201323. https:\/\/doi.org\/10.1054\/bjoc.1999.0956.","journal-title":"Br J Cancer"},{"issue":"7","key":"2196_CR12","doi-asserted-by":"publisher","first-page":"e021805","DOI":"10.1136\/bmjopen-2018-021805","volume":"8","author":"LJ Collin","year":"2018","unstructured":"Collin LJ, Cronin-Fenton DP, Ahern TP, et al. Cohort profile: the predictors of breast cancer recurrence (ProBe CaRE) premenopausal breast cancer cohort study in Denmark. BMJ Open. 2018;8(7):e021805. https:\/\/doi.org\/10.1136\/bmjopen-2018-021805.","journal-title":"BMJ Open"},{"issue":"6A","key":"2196_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3109\/02841868809091763","volume":"27","author":"KW Andersen","year":"1988","unstructured":"Andersen KW, Mouridsen HT, Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol Stockh Swed. 1988;27(6A):627\u201347. https:\/\/doi.org\/10.3109\/02841868809091763.","journal-title":"Acta Oncol Stockh Swed"},{"issue":"8","key":"2196_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541\u20139. https:\/\/doi.org\/10.1007\/s10654-014-9930-3.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"2196_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/0284186X.2017.1404638","volume":"57","author":"MB Jensen","year":"2018","unstructured":"Jensen MB, Laenkholm AV, Offersen BV, et al. The clinical database and implementation of treatment guidelines by the Danish breast cancer cooperative group in 2007\u20132016. Acta Oncol Stockh Swed. 2018;57(1):13\u20138. https:\/\/doi.org\/10.1080\/0284186X.2017.1404638.","journal-title":"Acta Oncol Stockh Swed"},{"issue":"8","key":"2196_CR16","first-page":"716","volume":"109","author":"KS McCarty","year":"1985","unstructured":"McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716\u201321.","journal-title":"Arch Pathol Lab Med"},{"issue":"30","key":"2196_CR17","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.1002\/sim.3458","volume":"27","author":"K Messer","year":"2008","unstructured":"Messer K, Natarajan L. Maximum likelihood, multiple imputation and regression calibration for measurement error adjustment. Stat Med. 2008;27(30):6332\u201350. https:\/\/doi.org\/10.1002\/sim.3458.","journal-title":"Stat Med"},{"issue":"4","key":"2196_CR18","doi-asserted-by":"publisher","first-page":"S1179","DOI":"10.1093\/ajcn\/65.4.1179S","volume":"65","author":"D Spiegelman","year":"1997","unstructured":"Spiegelman D, McDermott A, Rosner B. Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr. 1997;65(4):S1179\u201386. https:\/\/doi.org\/10.1093\/ajcn\/65.4.1179S.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2196_CR19","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.0006-341x.1999.01193.x","volume":"55","author":"CA Holcroft","year":"1999","unstructured":"Holcroft CA, Spiegelman D. Design of validation studies for estimating the odds ratio of exposure-disease relationships when exposure is misclassified. Biometrics. 1999;55(4):1193\u2013201. https:\/\/doi.org\/10.1111\/j.0006-341x.1999.01193.x.","journal-title":"Biometrics"},{"issue":"3","key":"2196_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/17512433.1.3.391","volume":"1","author":"MJ Zhang","year":"2008","unstructured":"Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol. 2008;1(3):391\u2013400. https:\/\/doi.org\/10.1586\/17512433.1.3.391.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2196_CR21","doi-asserted-by":"publisher","unstructured":"Sterne JAC, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338. https:\/\/doi.org\/10.1136\/bmj.b2393.","DOI":"10.1136\/bmj.b2393"},{"key":"2196_CR22","unstructured":"Rubin DB. Multiple imputation. In: Flexible imputation of missing data. Chapman and Hall\/CRC; 2018:29\u201362."},{"issue":"4","key":"2196_CR23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/aje\/kwq137","volume":"172","author":"M Spratt","year":"2010","unstructured":"Spratt M, Carpenter J, Sterne JAC, et al. Strategies for multiple imputation in longitudinal studies. Am J Epidemiol. 2010;172(4):478\u201387. https:\/\/doi.org\/10.1093\/aje\/kwq137.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"2196_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/0895-4356(88)90020-0","volume":"41","author":"S Greenland","year":"1988","unstructured":"Greenland S. Statistical uncertainty due to misclassification: implications for validation substudies. J Clin Epidemiol. 1988;41(12):1167\u201374. https:\/\/doi.org\/10.1016\/0895-4356(88)90020-0.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2196_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/sim.4780070704","volume":"7","author":"S Greenland","year":"1988","unstructured":"Greenland S. Variance Estimation for epidemiologic effect estimates under misclassification. Stat Med. 1988;7(7):745\u201357. https:\/\/doi.org\/10.1002\/sim.4780070704.","journal-title":"Stat Med"},{"key":"2196_CR26","unstructured":"Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data. Springer; 2011."},{"issue":"9","key":"2196_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/ijc.23350","volume":"122","author":"JM Day","year":"2008","unstructured":"Day JM, Foster PA, Tutill HJ, et al. 17beta-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer. 2008;122(9):1931\u201340. https:\/\/doi.org\/10.1002\/ijc.23350.","journal-title":"Int J Cancer"},{"issue":"3","key":"2196_CR28","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jsbmb.2009.02.006","volume":"114","author":"P Kruchten","year":"2009","unstructured":"Kruchten P, Werth R, Bey E, et al. Selective Inhibition of 17\u03b2-hydroxysteroid dehydrogenase type 1 (17\u03b2HSD1) reduces Estrogen responsive cell growth of T47-D breast cancer cells. J Steroid Biochem Mol Biol. 2009;114(3):200\u20136. https:\/\/doi.org\/10.1016\/j.jsbmb.2009.02.006.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2196_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.mce.2018.08.004","volume":"489","author":"T Heinosalo","year":"2019","unstructured":"Heinosalo T, Saarinen N, Poutanen M. Role of hydroxysteroid (17beta) dehydrogenase type 1 in reproductive tissues and hormone-dependent diseases. Mol Cell Endocrinol. 2019;489:9\u201331. https:\/\/doi.org\/10.1016\/j.mce.2018.08.004.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2196_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bjc.6602375","volume":"92","author":"C Gunnarsson","year":"2005","unstructured":"Gunnarsson C, Hellqvist E, St\u00e5l O. 17beta-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer. 2005;92(3):547\u201352. https:\/\/doi.org\/10.1038\/sj.bjc.6602375.","journal-title":"Br J Cancer"},{"issue":"1","key":"2196_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12672-009-0003-0","volume":"1","author":"SE Hankinson","year":"2010","unstructured":"Hankinson SE, Eliassen AH. Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer. 2010;1(1):2\u201310. https:\/\/doi.org\/10.1007\/s12672-009-0003-0.","journal-title":"Horm Cancer"},{"issue":"1","key":"2196_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsbmb.2008.12.012","volume":"114","author":"A Jansson","year":"2009","unstructured":"Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol. 2009;114(1):64\u20137. https:\/\/doi.org\/10.1016\/j.jsbmb.2008.12.012.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2196_CR33","doi-asserted-by":"publisher","unstructured":"Zhang CY, Chen J, Yin DC, Lin SX. The contribution of 17beta-Hydroxysteroid dehydrogenase type 1 to the Estradiol-Estrone ratio in Estrogen-Sensitive breast cancer cells. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0029835.","DOI":"10.1371\/journal.pone.0029835"},{"issue":"23","key":"2196_CR34","first-page":"8448","volume":"61","author":"C Gunnarsson","year":"2001","unstructured":"Gunnarsson C, Olsson BM, St\u00e5l O, Southeast Sweden Breast Cancer Group. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001;61(23):8448\u201351.","journal-title":"Cancer Res"},{"key":"2196_CR35","doi-asserted-by":"publisher","first-page":"105471","DOI":"10.1016\/j.jsbmb.2019.105471","volume":"195","author":"CY Zhang","year":"2019","unstructured":"Zhang CY, Calvo EL, Yang CQ, Liu J, Sang XY, Lin SX. Transcriptome of 17\u03b2-hydroxysteroid dehydrogenase type 2 plays both hormone-dependent and hormone-independent roles in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2019;195:105471. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105471.","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02196-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02196-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:44:02Z","timestamp":1769697842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02196-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2196"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02196-2","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for this study was granted by the Regional Ethics Committee of Central Denmark (journal number 1-10-72-22-13), the Danish Breast Cancer Group, and the Danish Data Protection Agency (Aarhus University number 2016-051-000001, #458), and adhered to the General Data Protection Regulation. The compilation and analysis of data in this study were conducted within the secure servers of Statistics Denmark, in accordance with Danish privacy laws.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LJC reports personal fees from Epidemiologic Research & Methods, LLC outside of the submitted work. TLL is a member of the Amgen Methods Advisory Council, for which he receives consulting fees and travel support. This work is outside of the submitted work. BE reports outside the submitted work an Advisory Role: Eli Lilly; Research funding: Institutional grants from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, and Seagen; and Travel, Accommodations, Expenses: Daiichi Sankyo, MSD, and Pfizer. The Department of Clinical Epidemiology, Aarhus University, receives funding for other studies from the European Medicines Agency and from companies in the form of research grants, unrelated to the current study. All other authors have no disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}